444620-69-3

Usage

Uses

Used in Scientific Research:
Tert-butyl 4-(isoquinolin-5-yl)piperazine-1-carboxylate is used as a research chemical for the investigation of its chemical properties and potential applications in various fields. Its unique structure and functional groups make it a valuable compound for exploring new chemical reactions and syntheses.
Used in Pharmaceutical Development:
In the pharmaceutical industry, tert-butyl 4-(isoquinolin-5-yl)piperazine-1-carboxylate is used as a starting material or intermediate in the synthesis of potential drug candidates. Its heterocyclic structure and functional groups can be further modified to create new compounds with therapeutic properties.
Used in Chemical Synthesis:
Tert-butyl 4-(isoquinolin-5-yl)piperazine-1-carboxylate is employed as a building block in the synthesis of more complex organic molecules. Its versatile structure allows for various chemical reactions, enabling the creation of a wide range of compounds with different properties and applications.
Used in Material Science:
In the field of material science, tert-butyl 4-(isoquinolin-5-yl)piperazine-1-carboxylate may be used to develop new materials with specific properties. Its heterocyclic structure and functional groups can contribute to the formation of novel materials with unique characteristics, such as improved stability, conductivity, or other desirable attributes.

InChI:InChI=1/C18H23N3O2/c1-18(2,3)23-17(22)21-11-9-20(10-12-21)16-6-4-5-14-13-19-8-7-15(14)16/h4-8,13H,9-12H2,1-3H3

Upstream product

• 34784-04-8 5-bromoisoquinoline 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 209733-17-5 5-(piperazin-1-yl)isoquinoline hydrochloride 
• 119-65-3 isoquinoline 
• 105685-17-4 5-(piperazin-1-yl)isoquinoline hydrochloride 

Relevant academic research and scientific papers

Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)

Factor XIa (FXIa) is a blood coagulation enzyme that is involved in the amplification of thrombin generation. Mounting evidence suggests that direct inhibition of FXIa can block pathologic thrombus formation while preserving normal hemostasis. Preclinical studies using a variety of approaches to reduce FXIa activity, including direct inhibitors of FXIa, have demonstrated good antithrombotic efficacy without increasing bleeding. On the basis of this potential, we targeted our efforts at identifying potent inhibitors of FXIa with a focus on discovering an acute antithrombotic agent for use in a hospital setting. Herein we describe the discovery of a potent FXIa clinical candidate, 55 (FXIa Ki = 0.7 nM), with excellent preclinical efficacy in thrombosis models and aqueous solubility suitable for intravenous administration. BMS-962212 is a reversible, direct, and highly selective small molecule inhibitor of FXIa.

SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

Synthesis and SAR of highly potent dual 5-HT1A and 5-HT 1B antagonists as potential antidepressant drugs

Novel 5-HT1 autoreceptor ligands based on the N-4-aryl-piperazinyl-N′-ethyl-5,6,7,8-tetrahydropyrido[4′, 3′:4,5]thieno[2,3-d]pyrimidin-4(3H)-one core are described. Aiming at antidepressants with a novel mode of action our objective was to identify potent antagonists showing balanced affinities and high selectivity for the 5-HT 1A and 5-HT1B receptors. Strategies for the development of dual 5-HT1A and 5-HT1B antagonists based on 1 and 2 as leads and the corresponding results are discussed. Isoquinoline analogue 33 displayed high affinity and an antagonistic mode of action for the 5-HT 1A and the 5-HT1B receptors and was characterized further with respect to selectivity, electrically stimulated [3H]5-HT release and in vivo efficacy.

Privileged structure-based ligands for melanocortin receptors - Tetrahydroquinolines, indoles, and aminotetralines

Substitution of the aryl sulfonamide moiety contained in MC4 agonist 1 with bicyclic heterocycles and aminotetralines produced compounds with MC4 activity. The heterocycles represent alternative privileged structures to that contained in 1. Compounds in which the polar group of the privileged structure was displayed in an endocyclic fashion were not as active as the parent agonist 1, while those with an exocyclic polar group afforded activity competitive with 1.

Substituted tetrahydroisoquinolines and uses thereof

The invention provides compounds of the formula: and pharmaceutically acceptable salts or prodrugs thereof, wherein, n, X, Y, R1, R2, R3, R4 and R5 are as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I.